MXC.L

MGC Pharmaceuticals Limited
MGC Pharmaceuticals - PDMR Notification
28th March 2024, 09:12
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 6895I
MGC Pharmaceuticals Limited
28 March 2024
 

 

MGC Pharmaceuticals Ltd.

PDMR Notification

28 March 2024

ASX, LSE: MXC

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) were issued a combined 240,000 unlisted options as approved at a meeting of shareholders on 18 March 2024. This notification is made in accordance the UK Market Abuse Regulations.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

(a)

Name

Daniel Robinson

2

Reason for the notification

 

(a)

Position

 

Non-Executive Director

(b)

Initial notification/amendment

 

Initial

(c)

If amendment: reason

 

n/a

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor


Full name of entity

MGC Pharmaceuticals Limited

 


Legal Entity Identifier Code

213800HRE3FQJ6RK4H10

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 

(a)

Description of the financial instrument, type of instrument

Unlisted options exercisable at A$0.42 on or before 28 March 2027.

(b)

Identification Code (ISIN)

 

AU000000MXC6

(c)

Nature of transaction

Grant of Options over Ordinary Shares

(d)

Currency

Price

Volume

Total


AUD

0.00

120,000

N/A


Aggregated information


AUD

0.00

120,000

N/A

(e)

Date of transaction

 

28 March 2024

(f)

Place of transaction

 

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

(a)

Name

Layton Mills

2

Reason for the notification

 

(a)

Position

 

Non-Executive Director

(b)

Initial notification/amendment

 

Initial

(c)

If amendment: reason

 

n/a

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor


Full name of entity

MGC Pharmaceuticals Limited

 


Legal Entity Identifier Code

213800HRE3FQJ6RK4H10

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 

(a)

Description of the financial instrument, type of instrument

Unlisted options exercisable at A$0.42 on or before 28 March 2027.

(b)

Identification Code (ISIN)

 

AU000000MXC6

(c)

Nature of transaction

Grant of Options over Ordinary Shares

(d)

Currency

Price

Volume

Total


AUD

0.00

120,000

N/A


Aggregated information


AUD

0.00

120,000

N/A

(e)

Date of transaction

 

28 March 2024

(f)

Place of transaction

 

Outside a trading venue

 

-Ends-

 

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd             

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@mgcpharma.co.uk

MGC Pharmaceuticals Ltd

Rowan Harland

Company Secretary

+61 8 6555 2950

info@mgcpharma.co.uk

 

UK IR/PR Advisers 

IFC Advisory

Graham Herring / Tim Metcalfe / Zach Cohen

+44 203 934 6630

mgcpharma@investor-focus.co.uk

UK Brokers

Oberon Capital

Aimee McCusker / Adam Pollock

+44 203 179 5300

aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGCGDXLGDDGSI]]>
TwitterFacebookLinkedIn